<DOC>
	<DOCNO>NCT00830869</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1 , dose escalation study IXAZOMIB . The primary purpose study determine safety profile , establish maximum tolerated dose , inform phase 2 dose IXAZOMIB administer intravenously patient nonhematologic malignancy .</brief_summary>
	<brief_title>A Phase 1 Study IXAZOMIB Adult Patients With Advanced Nonhematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : 1 . Male female patient 18 year old 2 . Eastern Cooperative Oncology Group performance status 02 3 . A diagnosis nonhematologic malignancy standard treatment longer effective . In expanded cohort , enrollment limit patient diagnosis NSCLC , head neck cancer ( squamous cell cancer ) , soft tissue sarcoma , prostate cancer 4 . Suitable venous access PK pharmacodynamic evaluation 5 . Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception abstain heterosexual intercourse Male patient agree practice 2 effective method contraception abstain heterosexual intercourse . 6 . Voluntary write consent must obtain 7 . Adequate clinical laboratory value screen period Patients meet follow exclusion criterion enrol study : 1 . Peripheral neuropathy â‰¥Grade 2 2 . Female patient lactate positive serum pregnancy test screen period 3 . Major surgery within 14 day first dose treatment 4 . Infection require systemic antibiotic therapy serious infection within 14 day first dose study treatment 5 . Lifethreatening illness unrelated cancer 6 . Diarrhea &gt; Grade 1 base NCI CTCAE categorization 7 . Systemic antineoplastic therapy / radiotherapy within 21 day first dose study treatment 8 . Systemic treatment prohibit medication 9 . Patient symptomatic brain metastasis 10 . Evidence current uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure ( CHF ) , angina , myocardial infarction within past 6 month 11 . QTc &gt; 470 millisecond ( msec ) 12lead electrocardiogram ( ECG ) obtain screen period 12 . Known human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C positive 13 . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol 14 . Treatment investigational product within 28 day first dose study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>